Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 25, 2024 (2 years ago)

Oxytocin 0.9% Sodium Chloride Injection USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP violations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Oxytocin 0.9% Sodium Chloride Injection USP, 30 units per 500 mL Single Dose Bag, Rx only, Fagron Sterile Services, Canton, MA NDC: 71506-028-59

Affected NDC 71506-0028-59

Compare with the code on your package — it is the most precise check available.

Drug: Oxytocin

Recalling firm
Fresenius Kabi Compounding, LLC
Origin
MA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0021-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Oxytocin recalls

See all
Class III · Low risk

Oxytocin synthetic

Labeling: Not Elsewhere Classified

Terminated Labeling / mix-up Denver Solutions, LLC DBA Leiters Health NDC 71449-157-70 D-0070-2024
Class II · Moderate risk

oxyTOCIN

Lack of Assurance of Sterility:Lack of validation data for sanitization cycles

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. D-1134-2023

Other recalls by Fresenius Kabi Compounding, LLC

All 2024 recalls